Polyostotic Fibrous Dysplasia
6
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (6)
Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome
Effects of Letrozole on Precocious Puberty Due to McCune Albright Syndrome
Bone Marrow Injection to Replace Diseased Bone in Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome
Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright Syndrome
A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome
Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty